Loading clinical trials...
Loading clinical trials...
Effects of ARA 290, a Non-hematopoietic Erythropoietin Analogue, on Glucose Tolerance, Insulin Secretion, Insulin Sensitivity and Long-term Glucose Control in Individuals With Prediabetes and/or Drug-naive Type 2 Diabetes; a Phase II Study.
Conditions
Interventions
ARA 290
Locations
1
Sweden
Dept of Endocrinology and Diabetes, Karolinska University Hospital
Stockholm, Sweden
Start Date
October 1, 2013
Primary Completion Date
June 1, 2014
Completion Date
December 1, 2015
Last Updated
September 3, 2015
NCT07374705
NCT05912647
NCT07011147
NCT07350694
NCT07126587
NCT06437782
Lead Sponsor
Claes-Göran Östenson
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions